Core Viewpoint - The company reported a revenue of 72.09 million yuan for the first half of 2025, marking a year-on-year increase of 20.85%, driven by growth in cytokine product sales and expansion into overseas markets. However, it also experienced a net loss of 24.22 million yuan, which is a 172% increase in losses compared to the previous year, primarily due to high R&D expenditures and a reduction in government subsidies [1][1][1] Financial Performance - Revenue for the first half of 2025 reached 72.09 million yuan, reflecting a 20.85% year-on-year growth [1] - Net profit loss amounted to 24.22 million yuan, which is a 172% increase in losses compared to the same period last year [1] - R&D expenses were 26.10 million yuan, accounting for 36.21% of total revenue [1] - Operating cash flow was negative at -14.08 million yuan, influenced by reduced sales collections and a decrease in subsidies [1] Project Updates - The completion of the fundraising projects "Core Raw Materials for Diagnosis and Innovative Diagnostic Reagents Industrialization Project" and "R&D Center Construction Project" has been postponed from September 2025 to September 2026 [1] - The location for the R&D center has been changed from Jinshan, Shanghai to Pudong New District, and the implementing entity has shifted from the subsidiary Chuangji Medical to Nearshore Technology [1] - The company stated that the postponement does not alter the investment content or total amount, and the adjustments were made based on a principle of prudence [1] Share Buyback Plan - The company approved a share buyback plan in October 2024, allowing for the repurchase of shares worth between 10 million to 20 million yuan using its own funds [1] - As of July 31, 2025, the company has not yet initiated the stock buyback [1]

Core Viewpoint - The recent financial report of Nearshore Protein (688137) indicates a significant increase in revenue but a substantial decline in net profit, highlighting challenges in profitability despite revenue growth [1] Financial Performance - Total revenue for the first half of 2025 reached 72.09 million yuan, a year-on-year increase of 20.85% compared to 59.65 million yuan in 2024 [1] - The net profit attributable to shareholders was -24.22 million yuan, representing a 172.0% decline from -8.91 million yuan in the previous year [1] - The gross profit margin improved to 64.47%, up 1.82% from 63.32% in 2024, while the net profit margin fell to -33.60%, a decrease of 125.07% [1] Cost and Expenses - Total selling, administrative, and financial expenses amounted to 32.55 million yuan, accounting for 45.15% of revenue, which is a 14.64% decrease year-on-year [1] - The company reported a significant drop in operating cash flow per share to -0.20 yuan, down 160.45% from 0.33 yuan in the previous year [1] Asset and Liability Management - Cash and cash equivalents decreased by 31.58% to 774 million yuan from 1.131 billion yuan [1] - Accounts receivable increased by 13.96% to 66.55 million yuan, indicating potential liquidity concerns [1] - Interest-bearing debt decreased by 32.24% to 11.99 million yuan, reflecting improved debt management [1] Investment and Market Sentiment - The company has a historical median ROIC of 6.33%, indicating average investment returns, with a notably poor performance in 2018 [3] - The company has faced three years of losses since its listing, suggesting a fragile business model [3] - The largest fund holding Nearshore Protein is Huashang Flexible Allocation Mixed A, with a recent net asset value increase of 2.3% [4]

Group 1 - The company, Nearshore Protein, announced the reappointment of Rongcheng Accounting Firm as its auditing institution for the fiscal year 2025 [2]

Core Points - The Supervisory Board of Suzhou Nearshore Protein Technology Co., Ltd. held its ninth meeting of the second session on August 27, 2025, where all resolutions were passed unanimously by the three attending supervisors [1][2][3][4] Group 1: Meeting Overview - The meeting was convened and chaired by Mr. Li Debin, and all procedures complied with relevant laws and regulations [1] - The meeting reviewed and approved the 2025 semi-annual report, confirming that it accurately reflects the company's financial status and operational results [1][2] Group 2: Financial Reports - The Supervisory Board approved the semi-annual fundraising storage and usage report, confirming compliance with relevant regulations and that funds were used appropriately without harming shareholder interests [2][3] - The board also approved the asset impairment provision report, stating that the provision aligns with accounting standards and accurately reflects the company's financial condition [3] Group 3: Fund Utilization - The board reviewed the proposal to use part of the excess raised funds, amounting to 72 million RMB, to permanently supplement working capital, which is expected to enhance operational efficiency and profitability [4] - This proposal was also unanimously approved and will be submitted for consideration at the company's first extraordinary general meeting of 2025 [4]

Group 1 - The company, Suzhou Novoprotein Technology Co., Ltd., is holding a shareholder meeting on September 12, 2025, at 15:00 [1][3][4] - The voting method for the shareholder meeting will combine on-site and online voting [1][3] - The online voting system will be the Shanghai Stock Exchange's shareholder meeting online voting system, available from 9:15 to 15:00 on the day of the meeting [1][3] Group 2 - The meeting will review non-cumulative voting proposals that were approved in the board and supervisory meetings held on August 27, 2025 [3] - There are no related shareholders that need to abstain from voting [3] - Shareholders must complete voting on all proposals before submission [3][5] Group 3 - Shareholders or their agents must register for the meeting by providing necessary documents, including identification and shareholder account information [5] - Registration will take place on September 11, 2025, from 8:30 to 17:00 [5] - The meeting will be held at Donghengsheng International Hotel, Suzhou [1][3]

Core Points - The company has prepared a special report on the use of raised funds for the first half of 2025, ensuring compliance with relevant regulations and confirming the accuracy of the report [1][2][5] Fundraising Overview - The company raised a total of RMB 1,754.386 million by issuing 17.54 million shares at a price of RMB 106.19 per share, with the total expected fundraising amount being RMB 1,754.386 million [1] - As of June 30, 2025, the cumulative investment of raised funds amounted to RMB 429.0863 million, with interest income received totaling RMB 91.1389 million and bank fees paid of RMB 0.0066 million, leaving a balance of RMB 1,404.2419 million [1][2] Fund Management - The company has established a fundraising management method to regulate the storage, approval, use, management, and supervision of raised funds, ensuring investor protection [2] - A tripartite supervision agreement has been signed with various banks to manage the special account for raised funds, with a balance of RMB 659.9814 million as of June 30, 2025 [2][3] Actual Use of Funds - As of June 30, 2025, the company has not used idle raised funds to temporarily supplement working capital [3] - The company has approved the use of idle raised funds for cash management, allowing for investments in safe and liquid products up to RMB 1 billion, with a total of RMB 744.2187 million in large transferable certificates of deposit as of June 30, 2025 [3][5] Other Fund Usage - The company has initiated a share repurchase plan using part of the raised funds, with a total repurchase amount between RMB 10 million and RMB 20 million, and has repurchased 404,337 shares for a total of RMB 11.9598 million as of June 30, 2025 [5][6] - There have been no changes in the direction of the raised funds or issues in the use and disclosure of the funds as of June 30, 2025 [5][6]

Core Viewpoint - The company is committed to enhancing operational quality and investor returns through its "Quality Improvement and Efficiency Enhancement Action Plan" for 2025, focusing on core competencies in recombinant protein technology and applications [1][2]. Group 1: Business Performance - The company achieved a revenue of 72.09 million yuan in the first half of 2025, representing a year-on-year increase of 20.85%, driven by improved management, product quality, and expansion into overseas markets [2]. - The recombinant protein business saw a significant growth of 43.66% year-on-year, while the overall customer base increased by 4.2% [2][6]. - The net profit attributable to shareholders was -24.22 million yuan, primarily due to high R&D and marketing investments aimed at high-quality development and reduced government subsidies [2][6]. Group 2: R&D and Innovation - The company emphasizes self-innovation, with 23 core technologies forming 7 comprehensive technology platforms, enhancing its capabilities in product development, production, and quality control [6][7]. - The company is actively developing solutions for various drug types, including RNA vaccines and antibody drugs, and is focusing on areas like organoids and three-dimensional genomics in life sciences [7][8]. Group 3: Investor Relations and Governance - The company has repurchased 404,337 shares for a total of approximately 11.96 million yuan to enhance investor confidence and maintain long-term investment value [8][9]. - The company adheres to strict information disclosure practices, ensuring transparency and communication with investors through multiple channels [9][10]. - The governance structure is continuously optimized to ensure compliance with legal regulations and to protect shareholder rights [10][11]. Group 4: Market Expansion - The company is expanding its overseas market presence by building localized teams and participating in international exhibitions related to antibody drugs and gene therapies [4][5]. - The number of overseas customers increased significantly, reflecting the company's successful market penetration strategies [5]. Group 5: Operational Efficiency - The company is implementing cost-reduction measures and enhancing production efficiency through supply chain integration and local sourcing of raw materials [3][6]. - Quality management systems such as GMP and ISO standards are strictly followed to ensure product safety and effectiveness [3][6]. Group 6: Future Outlook - The company plans to continue evaluating the execution of its action plan while focusing on core business areas and exploring new profit growth points [11]. - The commitment to sustainable long-term returns for investors remains a priority, alongside maintaining operational excellence [11].

Group 1 - The company reported a credit impairment loss of 82.76 thousand yuan, with accounts receivable bad debt loss of 90.43 thousand yuan and other receivables bad debt recovery of 7.67 thousand yuan [2] - The company recognized an asset impairment loss of 1,812.77 thousand yuan, entirely attributed to inventory write-downs [2] - The total impact of the impairment provisions on the company's consolidated profit amounted to 1,730.01 thousand yuan [2] Group 2 - The impairment provisions were made in accordance with the accounting policies and standards to reflect the financial status and operating results as of June 30, 2025 [1] - The impairment losses were not audited by the accounting firm, and investors are advised to be cautious regarding investment risks [2]

Core Viewpoint - Suzhou Nearshore Protein Technology Co., Ltd. plans to use part of its oversubscribed funds amounting to RMB 72 million for permanent working capital, which represents 29.73% of the total oversubscribed funds, pending approval from the shareholders' meeting [1][5]. Fundraising Overview - The company raised a net amount of RMB 1,742.20 million from its initial public offering, with total oversubscribed funds amounting to RMB 242.20 million [2][4]. - The total investment amount for the fundraising projects is RMB 1,500 million, with the planned use of funds from this issuance also being RMB 1,500 million [2]. Plan for Using Oversubscribed Funds - The decision to use RMB 72 million of the oversubscribed funds for working capital is aimed at meeting the company's liquidity needs and improving the efficiency of fund usage, while ensuring that the fundraising projects continue as planned [2][3]. - The company commits that the cumulative use of oversubscribed funds for permanent working capital will not exceed 30% of the total oversubscribed funds within any twelve-month period [3][4]. Review and Approval Process - The board of directors and the supervisory board have approved the proposal to use part of the oversubscribed funds for working capital, which will be submitted for further approval at the shareholders' meeting [5]. - The supervisory board believes that the decision complies with relevant regulations and does not harm the interests of the company or its shareholders, particularly minority shareholders [5].

证券代码：688137 证券简称：近岸蛋白 公告编号：2025-033 苏州近岸蛋白质科技股份有限公司 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： ? 拟聘任的会计师事务所名称：容诚会计师事务所（特殊普通合伙）（ 以下简称"容诚"） ? 本事项尚需提交公司股东会审议。 一、拟聘任会计师事务所的基本情况 （一）机构信息 容诚会计师事务所（特殊普通合伙）由原华普天健会计师事务所（特殊普通 合伙）更名而来，初始成立于1988年8月，2013年12月10日改制为特殊普通合伙 企业，是国内最早获准从事证券服务业务的会计师事务所之一，长期从事证券服 务业务。注册地址为北京市西城区阜成门外大街22号1幢10层1001-1至1001-26， 首席合伙人刘维。 截至2024年12月31日，容诚会计师事务所共有合伙人196人，共有注册会计 师1,549人，其中781人签署过证券服务业务审计报告。 二、项目信息 项目合伙人：李飞，2015年成为中国注册会计师，2011年开始从事上市公 司审计业务，2015年开始在容诚会计师事 ...